TICKERNERD
Menu
CRVSCRVSHealthcare · Biotechnology

CRVS Stock Forecast: Corvus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$10
−1.92% on the day

The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. hold a median 12-month price target of $32 — +213.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$888.3M
Ticker Nerd rank
54 / 100
Median analyst target
$32
Analysts covering
8
Revenue$0.0
Operating income−$19.3M
Net income−$18.0M
Free cash flow−$16.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
−26.7%
YTD
+32.6%
1Y
+45.9%
From 52W high
−60.0%
From 52W low
+57.1%
$7
$26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corvus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
82
Quality
78
Momentum
68
Volatility
51
Growth
48
Size
46
Accruals
44
Issuance
40
Revisions
32

Value (82): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (32): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26CRVSHigh $42Median $32Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $27Median $32High $42

The green dot is the last close — the median target sits +213.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Apr 2026Goldman SachsInitiatesBuy$40
17 Apr 2026Goldman SachsInitiatesBuy—
13 Mar 2026OppenheimerReiteratesOutperform—
22 Jan 2026JefferiesMaintainsBuy—
21 Jan 2026BarclaysMaintainsOverweight—
21 Jan 2026OppenheimerMaintainsOutperform—
20 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Oct 2025BarclaysInitiatesOverweight—
20 May 2025MizuhoMaintainsOutperform—
9 May 2025OppenheimerReiteratesOutperform—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025OppenheimerMaintainsOutperform—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
2 Jan 2025HC Wainwright & Co.InitiatesBuy—
13 Nov 2024OppenheimerReiteratesOutperform—
16 Sept 2024Ladenburg ThalmannMaintainsBuy—
7 May 2024OppenheimerMaintainsOutperform—
1 Apr 2024Cantor FitzgeraldReiteratesOverweight—
27 Mar 2024MizuhoMaintainsNeutral—
20 Mar 2024OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Corvus Pharmaceuticals, Inc. returned +45.9% against +16.2% for the S&P 500, dividends included.

CRVS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26CRVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Corvus Pharmaceuticals, Inc. (CRVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−55.5×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
3.9×

Cheaper than 25% of US stocks

EV / EBITDA
−11.9×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−35.4%

Higher than 26% of US stocks

Return on assets
−21.7%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corvus Pharmaceuticals, Inc. (CRVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corvus Pharmaceuticals, Inc. has a market value of $888.3M and an enterprise value of $673.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$54.1M.

  • Diluted earnings per share, trailing twelve months: $−0.61.

  • Free cash flow in the twelve months to 30 June 2026: −$45.2M.

  • Shares outstanding: 84.1M.

  • Trailing P/E: −55.5×; forward P/E: −9.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Corvus Pharmaceuticals, Inc. employs 37 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CRVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRVSCorvus Pharmaceuticals, Inc.$888.3M
54
ODTXOdyssey Therapeutics, Inc.$854.8M
1
TBPHTheravance Biopharma, Inc.$857.7M
—
SLBTSL Science Holding Ltd.$852.4M
1
GLUEMonte Rosa Therapeutics, Inc.$871.8M
63
SANASana Biotechnology, Inc.$835.2M
31
ALMSAlumis, Inc.$886.6M
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corvus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRVS news & analysis

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

GlobeNewsWire · 30 Sept 2026positive

Corvus Pharmaceuticals announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for patients with hidradenitis suppurativa. The trial will evaluate the drug in this additional indication.

Why it matters — This expands soquelitinib's clinical pipeline into a new disease area, offering CRVS watchers progress on a potential additional therapeutic application.

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Corvus Pharmaceuticals announced that members of its leadership team will hold one-on-one meetings with investors and participate in a fireside chat presentation at the 2026 Cantor Global Healthcare Conference in New York, NY, on September 10, 2026 at 1:00 pm ET.

Why it matters — A CRVS watcher would care because the company's participation at a major healthcare conference offers potential visibility and engagement opportunities with investors.

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

GlobeNewsWire · 27 Aug 2026positive

Corvus Pharmaceuticals announced the publication in the journal Blood of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma. The data support the ongoing registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, as well as trials in atopic dermatitis, hidradenitis suppurativa, and asthma.

Why it matters — The publication of final Phase 1 data in a peer-reviewed journal lends validation to soquelitinib's novel ITK inhibition mechanism and supports the company's ongoing clinical development across multiple indications.

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Corvus Pharmaceuticals' (CRVS) Q2 2026 earnings call. The item consists solely of the earnings call transcript headline and source.

Why it matters — A CRVS watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly results and management discussion.

Corvus Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Corvus Pharmaceuticals reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor. The company outlined expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.

Why it matters — A CRVS watcher would care because the company's increased spending is tied to advancing soquelitinib across multiple key clinical programs and upcoming milestones.

FAQ

Frequently asked questions about CRVS stock

What is the CRVS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. have a median 12-month price target of $32, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRVS stock a buy right now?

Of the 8 analysts covering Corvus Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corvus Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRVS?

As at 8 Oct 2026, Corvus Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (82 of 100).

Will CRVS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +213.4% from the last close, and Ticker Nerd's factor model ranks Corvus Pharmaceuticals, Inc. 54 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRVS stock forecast for 2030?

No analyst covering Corvus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.

How has CRVS stock performed over the past year?

Corvus Pharmaceuticals, Inc. returned +45.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer.

What is the latest news on CRVS?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa". Corvus Pharmaceuticals announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for patients with hidradenitis suppurativa. The trial will evaluate the drug in this additional indication.

Company

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.

CEO Dr. Richard A. Miller M.D. · 37 employees · United States · https://www.corvuspharma.com